Salsabilla Puteri Wandira, . (2026) ANALISIS EFEKTIVITAS BIAYA PENGGUNAAN TERAPI SIMVASTATIN DAN ATORVASTATIN PADA PASIEN PENYAKIT JANTUNG KORONER DI RSUP PERSAHABATAN PERIODE 2024. Skripsi thesis, Universitas Pembangunan Nasional Veteran Jakarta.
![[img]](http://repository.upnvj.ac.id/style/images/fileicons/text.png) |
Text
ABSTRAK.pdf Download (232kB) |
|
Text
AWAL.pdf Download (585kB) |
|
Text
BAB 1.pdf Restricted to Repository UPNVJ Only Download (251kB) |
|
Text
BAB 2.pdf Restricted to Repository UPNVJ Only Download (543kB) |
|
Text
BAB 3.pdf Restricted to Repository UPNVJ Only Download (315kB) |
|
Text
BAB 4.pdf Restricted to Repository UPNVJ Only Download (327kB) |
|
Text
BAB 5.pdf Download (223kB) |
|
Text
DAFTAR PUSTAKA.pdf Download (295kB) |
|
Text
RIWAYAT HIDUP.pdf Restricted to Repository staff only Download (168kB) |
|
Text
LAMPIRAN.pdf Restricted to Repository UPNVJ Only Download (1MB) |
|
Text
HASIL PLAGIARISME.pdf Restricted to Repository staff only Download (5MB) |
|
Text
ARTIKEL ILMIAH.pdf Restricted to Repository staff only Download (452kB) |
Abstract
Coronary Heart Disease (CHD) ranks first in mortality rates worldwide. CHD is not only observed from a clinical perspective but also poses a significant economic burden on healthcare systems. The increasing incidence of CHD is associated with several risk factors, one of which is dyslipidemia. This study aimed to analyze and compare the cost-effectiveness of antidyslipidemic therapies, simvastatin and atorvastatin, using the Average Cost-Effectiveness Ratio (ACER) and Incremental Cost-Effectiveness Ratio (ICER) calculations. The study employed an observational analytic design with a cross-sectional approach and was conducted in accordance with the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) guidelines. Sample consisted of 21 outpatient CHD patients, including 13 patients atorvastatin and 8 patients simvastatin. Therapeutic effectiveness was assessed based on the proportion of patients low-density lipoprotein (LDL) reduction of 18-55%, while the costs evaluated were direct medical costs. The results showed that the total direct medical costs for atorvastatin and simvastatin were Rp4.864.867 and Rp4.303.322 with effectiveness values of 76.92% and 87.50%. Simvastatin as dominating due to higher effectiveness with lower costs, whereas atorvastatin as dominated because of lower effectiveness with higher costs, therefore ICER calculation was not required. In addition, the ACER value of simvastatin was lower than that of atorvastatin, amounting to Rp49.181 and Rp63.243. Based on these findings, simvastatin was considered more cost-effective.
| Item Type: | Thesis (Skripsi) |
|---|---|
| Additional Information: | [No.Panggil: 2210212022] [Pembimbing: Riswandy Wasir] [Penguji 1: Wafa] [Penguji 2: Primayanti Nurul Ilmi] |
| Uncontrolled Keywords: | ACER, Atorvastatin, Coronary Heart Disease, ICER, Simvastatin |
| Subjects: | R Medicine > RS Pharmacy and materia medica R Medicine > RZ Other systems of medicine |
| Divisions: | Fakultas Kedokteran > Program Studi Farmasi (S1) |
| Depositing User: | SALSABILLA PUTERI WANDIRA |
| Date Deposited: | 27 Aug 2026 13:51 |
| Last Modified: | 27 Aug 2026 13:51 |
| URI: | http://repository.upnvj.ac.id/id/eprint/50559 |
Actions (login required)
 |
View Item |